期刊
JOURNAL OF CYSTIC FIBROSIS
卷 14, 期 2, 页码 262-266出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jcf.2014.09.013
关键词
Pulmonary exacerbation; Antibiotics; Pseudomonas aeruginosa; Biofilm
资金
- Innovotech Inc.
- National Research Council Industrial Research Assistance Program (NRC-IRAP) of Alberta
This study aimed to determine whether antimicrobial susceptibility testing of Pseudomonas aeruginosa grown as a biofilm, rather than planktonically, improves efficacy of antibiotic treatment for pulmonary exacerbations. This was a multicenter randomized, double-blind controlled trial of 14 days of intravenous antibiotic treatment for pulmonary exacerbations chosen based on conventional vs. biofilm antimicrobial susceptibility results in CF patients with chronic P. aeruginosa infection. There were 74 exacerbations in 39 patients. A total of 46% (12/26) exacerbations in the conventional group compared to 40% (19/48) exacerbations in the biofilm group achieved a >= 3 log drop in P. aeruginosa sputum density (difference -0.03, 95% CI -0.5 to 0.4, p = 0.9). Lung function improvements were similar in both groups. Biofilm antimicrobial susceptibility testing did not lead to improved microbiological or clinical outcomes compared to conventional methods in the treatment of pulmonary exacerbations in CF patients with chronic P. aeruginosa. (C) 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据